Passa al contenuto
Merck

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

SML2841

Tarenflurbil

≥98% (HPLC)

Sinonimo/i:

(R)-(−)-2-Fluoro-α-methyl-4-biphenylacetic acid, αR)-2-Fluoro-α-methyl[1,1′-biphenyl]-4-acetic acid, (-)-(R)-Flurbiprofen, (2R)-2-(3-Fluoro-4-phenylphenyl)propanoic acid, (R)-Flurbiprofen, Flurizan, R-flurbiprofen, (R)-2-Flurbiprofen, Tarenflurbil

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
10 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 27.90
CHF 23.71
50 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 110.00
CHF 93.50

Informazioni su questo articolo

Formula condensata:
C6H5C6H3(F)CH(CH3)CO2H
Numero CAS:
51543-40-9
Peso molecolare:
244.26
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00869714
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

CHF 23.71

Prezzo di listinoCHF 27.90Risparmia il 15%
Promozione valida solo online
Per conoscere la disponibilità, visualizza il carrello
​
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[C@@H](C(O)=O)c1ccc(c(F)c1)-c2ccccc2

InChI

1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1

InChI key

SYTBZMRGLBWNTM-SNVBAGLBSA-N

Biochem/physiol Actions

Tarenflurbil (or R-flurbiprofen) is an R enantiomer of racemic NSAID flurbiprofen that does not inhibit either cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2). Tarenflurbil potently reduces levels of beta amyloid in human cells through direct inhibition of γ-secretase.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
SML1914F8514SML2281
Tarenflurbil ≥98% (HPLC)

Sigma-Aldrich

SML2841

Tarenflurbil

TUG-891 ≥98% (HPLC)

Sigma-Aldrich

SML1914

TUG-891

Flurbiprofen cyclooxygenase inhibitor

Sigma-Aldrich

F8514

Flurbiprofen

BAY 60-2770 ≥98% (HPLC)

Sigma-Aldrich

SML2281

BAY 60-2770

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

-

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

2-8°C

storage temp.

room temp

storage temp.

-

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

methanol: 50 mg/mL

solubility

DMSO: 2 mg/mL, clear

color

white to beige

color

white to beige

color

white to off-white

color

white to beige

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Oral - Repr. 2 - Skin Sens. 1B

Classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000515267
0000515268
0000515268
0000515267
0000504723

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Jason L Eriksen et al.
The Journal of clinical investigation, 112(3), 440-449 (2003-08-05)
Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower
T Morihara et al.
Journal of neurochemistry, 83(4), 1009-1012 (2002-11-08)
Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress beta-amyloid (Abeta) accumulation in vivo and Abeta42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been
Ling Rong Wong et al.
The Journal of pharmacy and pharmacology, 70(1), 59-69 (2017-10-17)
R-flurbiprofen (R-FP) was found to offer neuroprotective effects by inhibiting mitochondrial calcium overload induced by β-amyloid peptide toxicity in Alzheimer's disease (AD). However, poor brain penetration after oral administration posed a challenge to its further development for AD treatment. In

Numero articolo commerciale globale

SKUGTIN
SML2841-10MG04061842330553
SML2841-50MG04061842330560

Questions

Reviews

No rating value

Active Filters